AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 162 min read$CYTK

Cytokinetics Inc (CYTK) Director Robert Landry Sells 1,000 Share

Cytokinetics Inc (CYTK) Director Robert Landry sold 1,000 shares on 2026-09-15, reducing his holding to 8,184 shares. The sale occurred at $72.13 per share, with the company's market cap at $9.64 billion. Over the past year, Landry sold 2,000 shares and bought none, aligning with a broader trend of 79 insider sells and 0 buys. GuruFocus values CYTK at $220.41, suggesting a possible value trap with a 0.33 price-to-GF-Value ratio.

Original reporting
gurufocus.com
Published Sep 16, 2026, 12:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 4:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CYTK
Bearish
medium confidence
Mentioned
$CYTK
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$CYTKBearishLow
01

Why it matters

The disclosed insider sale adds a negative data point for CYTK, potentially influencing short-term price action.

02

Market read

Insider selling at a biotech with a large valuation discount may prompt traders to reassess risk exposure.

03

What to watch

GuruFocus valuation suggests a deep discount; institutional guru buying may offset insider sell pressure.

Relevance 4/10Novelty 4/10Timing: sale reported on Sep 15, 2026

Background

The article reports a Form 4 filing showing a director's recent stock sale and places it in the context of overall insider activity and valuation metrics.

Company-level read

Ticker impact

$CYTKBearishMedium confidence
Context

Director Robert Landry sold 1,000 CYTK shares on Sep 15, continuing a pattern of insider selling.

Expected impact

Potential short-term downside as investors interpret continued insider selling as a bearish signal.

Evidence & confidence

While the dollar amount ($72k) is modest, the cumulative insider sell volume (79 shares sold, zero buys) signals a negative sentiment trend.

Market effects

Sector

Biopharma sector may see heightened scrutiny of insider activity, but no broad sector impact.

Regional

Limited to U.S. biotech investors; no regional effect.

Global

Low global relevance; only affects CYTK shareholders.

Counterpoint

What could challenge this read

Insider selling could be unrelated personal liquidity needs; the stock remains undervalued at a 0.33 price-to-GF-Value ratio.

Key entities

  • Company
    Cytokinetics Inc

    Biopharmaceutical company developing muscle function therapeutics.

  • Director
    Robert Landry

    CYTK board member who sold 1,000 shares.

Read at source← All news

Related articles

SEP 12
$CYTKMedAI 8/10

Cytokinetics (CYTK) Shares In Focus After New Phase 3 Aficamten Data

Cytokinetics (CYTK) reported detailed Phase 3 trial results for aficamten, showing efficacy and safety in hypertrophic cardiomyopathy. The company plans to file a supplemental drug application, aiming to expand its cardiology franchise. Cytokinetics has a market cap of $10.3 billion and focuses on muscle-related diseases. Regulatory uncertainty and a small pipeline remain risks.

simplywall.st2 min
SEP 11
$CYTKMed

Cantor Fitzgerald reiterates Overweight on Cytokinetics stock

Cantor Fitzgerald reiterated an Overweight rating on Cytokinetics (CYTK), citing strong commercial and regulatory outlooks. The stock has risen 38% over the past year, trading at $73.62 with a $10.23B market cap. Analysts have raised earnings estimates, though profitability is not expected this year. Management expects 50% new prescription share by year-end and potential REMS relaxation. Cytokinetics reported Q2 sales of $25.3M for Myqorzo, exceeding estimates. Barclays and Citizens raised price

investing.com2 min
SEP 8
$CYTKMedAI 8/10

Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?

Cytokinetics (NASDAQ:CYTK) reported late-stage trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), meeting primary goals of improving symptoms and quality of life. The study showed 53% of patients on aficamten improved in key areas vs. 13% on placebo, but lacked significant structural or cardiovascular benefits. The company plans a US marketing application in Q4 2026. Analysts forecast peak sales of over $5 billion for Myqorzo, but investors expressed concerns over

finance.yahoo.com2 min
SEP 2
$CYTKMedAI 8/10

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics (CYTK) presented additional results from ACACIA-HCM and MAPLE-HCM studies at the European Society of Cardiology Congress 2026, showing aficamten's benefits in non-obstructive HCM (nHCM) and superiority over metoprolol in obstructive HCM (oHCM). CYTK plans to submit an sNDA for aficamten in nHCM in Q4 2026. Myqorzo (aficamten) faces competition from Bristol Myers Squibb's (BMY) Camzyos and Edgewise Therapeutics' (EWTX) EDG-7500. CYTK shares are up 12.4% YTD, trading at 26.6X forward

finance.yahoo.com3 min
AUG 31
$CYTKMedAI 9/10

What's Going On With Cytokinetics Stock Today? - Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) reported positive results from its ACACIA-HCM Phase 3 trial of aficamten for non-obstructive hypertrophic cardiomyopathy, meeting primary endpoints and showing improvements in symptoms and exercise performance. The drug showed benefits in five key areas, but some safety concerns were noted. Cytokinetics plans to file for FDA approval in Q4 2026. Shares fell 3.19% to $69.79.

benzinga.com2 min